Medizintechnische Entwicklung der hyperthermen Pressurized IntraPeritoneal Aerosol Chemotherapy (hPIPAC)

DSpace Repository


Dateien:

URI: http://hdl.handle.net/10900/155047
http://nbn-resolving.de/urn:nbn:de:bsz:21-dspace-1550479
http://dx.doi.org/10.15496/publikation-96384
http://nbn-resolving.org/urn:nbn:de:bsz:21-dspace-1550471
http://nbn-resolving.org/urn:nbn:de:bsz:21-dspace-1550478
Dokumentart: PhDThesis
Date: 2024-07-15
Source: Erschienen in: Bachmann, C., Sautkin, I., Nadiradze, G. et al. Technology development of hyperthermic pressurized intraperitoneal aerosol chemotherapy (hPIPAC). Surg Endosc 35, 6358–6365 (2021). https://doi.org/10.1007/s00464-021-08567-y
Language: English
Faculty: 4 Medizinische Fakultät
Department: Medizin
Advisor: Königsrainer, Alfred (Prof. Dr.)
Day of Oral Examination: 2021-03-18
DDC Classifikation: 610 - Medicine and health
Other Keywords: PIPAC
hPIPAC
Bauchfellkrebs
Intraperitoneal Chemotherapy
License: http://tobias-lib.uni-tuebingen.de/doku/lic_ohne_pod.php?la=de http://tobias-lib.uni-tuebingen.de/doku/lic_ohne_pod.php?la=en
Show full item record

Abstract:

Background Optimized drug delivery systems are needed for intraperitoneal chemotherapy. The aim of this study was to develop a technology for applying pressurized intraperitoneal aerosol chemotherapy (PIPAC) under hyperthermic conditions (hPIPAC). Methods This is an ex-vivo study in an inverted bovine urinary bladder (IBUB). Hyperthermia was established using a modified industry-standard device (Humigard). Two entry and one exit ports were placed. Warm-humid CO2 was insufflated in the IBUB placed in a normothermic bath to simulate body thermal inertia. The temperature of the aerosol, tissue, and water bath was measured in real-time. Results Therapeutic hyperthermia (target tissue temperature 41–43 °C) could be established and maintained over 30 min. In the first phase (insufflation phase), tissue hyperthermia was created by insufflating continuously warm-humid CO2. In the second phase (aerosolization phase), chemotherapeutic drugs were heated up and aerosolized into the IBUB. In a third phase (application phase), hyperthermia was maintained within the therapeutic range using an endoscopic infrared heating device. In a fourth phase, the toxic aerosol was discarded using a closed aerosol waste system (CAWS). Discussion We introduce a simple and effective technology for hPIPAC. hPIPAC is feasible in an ex-vivo model by using a combination of industry-standard medical devices after modification. Potential pharmacological and biological advantages of hPIPAC over PIPAC should now be evaluated.

This item appears in the following Collection(s)